Cite
HARVARD Citation
Mascarenhas, J. et al. (2020). A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leukemia research. p. . [Online].